Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010☆ , ☆☆ ,★,★★

Abstract In 2009–2010, 3646 urinary tract isolates of Enterobacteriaceae spp. were isolated from hospitalized patients in North America and Europe. Extended-spectrum beta-lactamase (ESBL) production was detected in 8.5% and 8.8% of Escherichia coli and Klebsiella pneumoniae , respectively, in North America and in 17.6% and 38.9% for Europe, respectively. The carbapenems (ertapenem and imipenem) were the most active agents in vitro, with ampicillin–sulbactam the least active. Molecular characterization of about 50% of ESBL-positive isolates identified the presence of bla CTX-M genes in over 90% of Escherichia coli from both continents. bla KPC was more common in North American isolates of K. pneumoniae than in European isolates (21.4% versus 6.9%). bla TEM and AmpC genes were infrequent. Enterobacteriaceae spp. isolated from hospitalized patients with urinary tract infections in both North America and Europe are often resistant to commonly used antimicrobials with bla CTX-M genes common in both Escherichia coli and K. pneumoniae .